The elite and stochastic model for iPS cell generation: Multilineage-differentiating stress enduring (Muse) cells are readily reprogrammable into iPS cells

Cytometry Part A

Volumn 83 A, Issue 1, 2013, Pages 18-26

  Wakao, Shohei ^a   Kitada, Masaaki ^a   Dezawa, Mari ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adult stem cells; Elite model; IPS cells; Mesenchymal stem cells

Indexed keywords

CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOLOGY; FIBROBLAST; HUMAN; MESENCHYMAL STROMA CELL; PLURIPOTENT STEM CELL; REVIEW; STATISTICAL MODEL;

CELL DIFFERENTIATION; CELL PROLIFERATION; FIBROBLASTS; HUMANS; MESENCHYMAL STROMAL CELLS; MODELS, STATISTICAL; PLURIPOTENT STEM CELLS;

EID: 84871656447     PISSN: 15524922     EISSN: 15524930     Source Type: Journal    
DOI: 10.1002/cyto.a.22069     Document Type: Review

References (80)

1. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676.
2. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, et al. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861-872.
3. Puri MC, Nagy A. Concise review: Embryonic stem cells versus induced pluripotent stem cells: The game is on. Stem Cells 2012; 30: 10-14.
4. Polo JM, Liu S, Figueroa ME, Kulalert W, Eminli S, et al. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat Biotechnol 2010; 28: 848-855.
5. Chin MH, Mason MJ, Xie W, Volinia S, Singer M, et al. Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell 2009; 5: 111-123.
6. Kim K, Doi A, Wen B, Ng K, Zhao R, et al. Epigenetic memory in induced pluripotent stem cells. Nature 2010; 467: 285-290.
7. Zhao T, Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 2011; 474: 212-215.
8. Yamanaka S. Elite and stochastic models for induced pluripotent stem cell generation. Nature 2009; 460: 49-52.
9. Hanna J, Saha K, Pando B, van Zon J, Lengner CJ, et al. Direct cell reprogramming is a stochastic process amenable to acceleration. Nature 2009; 462: 595-601.
10. Aasen T, Raya A, Barrero MJ, Garreta E, Consiglio A, et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat Biotechnol 2008; 26: 1276-1284.
11. Sun N, Panetta NJ, Gupta DM, Wilson KD, Lee A, et al. Feeder-free derivation of induced pluripotent stem cells from adult human adipose stem cells. Proc Natl Acad Sci USA 2009; 106: 15720-15725.
12. Miyoshi K, Tsuji D, Kudoh K, Satomura K, Muto T, et al. Generation of human induced pluripotent stem cells from oral mucosa. J Biosci Bioeng 2010; 110: 345-350.
13. Tamaoki N, Takahashi K, Tanaka T, Ichisaka T, Aoki H, et al. Dental pulp cells for induced pluripotent stem cell banking. J Dent Res 2010; 89: 773-778.
14. Giorgetti A, Montserrat N, Aasen T, Gonzalez F, Rodriguez-Piza I, et al. Generation of induced pluripotent stem cells from human cord blood using OCT4 and SOX2. Cell Stem Cell 2009; 5: 353-357.
15. Loh YH, Agarwal S, Park IH, Urbach A, Huo H, et al. Generation of induced pluripotent stem cells from human blood. Blood 2009; 113: 5476-5479.
16. Seki T, Yuasa S, Oda M, Egashira T, Yae K, et al. Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell 2010; 7: 11-14.
17. Nishino K, Toyoda M, Yamazaki-Inoue M, Fukawatase Y, Chikazawa E, et al. DNA methylation dynamics in human induced pluripotent stem cells over time. PLoS Genet 2011; 7: e1002085.
18. Utikal J, Maherali N, Kulalert W, Hochedlinger K. Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells. J Cell Sci 2009; 122: 3502-3510.
19. Ye Z, Zhan H, Mali P, Dowey S, Williams DM, et al. Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood 2009; 114: 5473-5480.
20. Abollo-Jimenez F, Jimenez R, Cobaleda C. Physiological cellular reprogramming and cancer. Semin Cancer Biol 2010; 20: 98-106.
21. Ou L, Wang X, Zou F. Is iPS cell the panacea? IUBMB Life 2010; 62: 170-175.
22. Byrne JA, Nguyen HN, Reijo Pera RA. Enhanced generation of induced pluripotent stem cells from a subpopulation of human fibroblasts. PLoS One 2009; 4: e7118.
23. Wakao S, Kitada M, Kuroda Y, Shigemoto T, Matsuse D, et al. Multilineage-differentiating stress-enduring (Muse) cells are a primary source of induced pluripotent stem cells in human fibroblasts. Proc Natl Acad Sci USA 2011; 108: 9875-9880.
24. Nishimura EK, Jordan SA, Oshima H, Yoshida H, Osawa M, et al. Dominant role of the niche in melanocyte stem-cell fate determination. Nature 2002; 416: 854-860.
25. Murga M, Yao L, Tosato G. Derivation of endothelial cells from CD34- umbilical cord blood. Stem Cells 2004; 22: 385-395.
26. Middleton J, Americh L, Gayon R, Julien D, Mansat M, et al. A comparative study of endothelial cell markers expressed in chronically inflamed human tissues: MECA-79, Duffy antigen receptor for chemokines, von Willebrand factor, CD31, CD34, CD105 and CD146. J Pathol 2005; 206: 260-268.
27. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008; 3: 301-313.
28. Nagoshi N, Shibata S, Kubota Y, Nakamura M, Nagai Y, et al. Ontogeny and multipotency of neural crest-derived stem cells in mouse bone marrow, dorsal root ganglia, and whisker pad. Cell Stem Cell 2008; 2: 392-403.
29. Fernandes KJ, McKenzie IA, Mill P, Smith KM, Akhavan M, et al. A dermal niche for multipotent adult skin-derived precursor cells. Nat Cell Biol 2004; 6: 1082-1093.
30. Biernaskie J, Paris M, Morozova O, Fagan BM, Marra M, et al. SKPs derive from hair follicle precursors and exhibit properties of adult dermal stem cells. Cell Stem Cell 2009; 5: 610-623.
31. Gimble JM, Katz AJ, Bunnell BA. Adipose-derived stem cells for regenerative medicine. Circ Res 2007; 100: 1249-1260.
32. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-147.
33. Kuroda Y, Kitada M, Wakao S, Nishikawa K, Tanimura Y, et al. Unique multipotent cells in adult human mesenchymal cell populations. Proc Natl Acad Sci USA 2010; 107: 8639-8643.
34. Kuznetsov SA, Mankani MH, Leet AI, Ziran N, Gronthos S, et al. Circulating connective tissue precursors: Extreme rarity in humans and chondrogenic potential in guinea pigs. Stem Cells 2007; 25: 1830-1839.
35. Kuznetsov SA, Riminucci M, Ziran N, Tsutsui TW, Corsi A, et al. The interplay of osteogenesis and hematopoiesis: Expression of a constitutively active PTH/PTHrP receptor in osteogenic cells perturbs the establishment of hematopoiesis in bone and of skeletal stem cells in the bone marrow. J Cell Biol 2004; 167: 1113-1122.
36. Koerner J, Nesic D, Romero JD, Brehm W, Mainil-Varlet P, et al. Equine peripheral blood-derived progenitors in comparison to bone marrow-derived mesenchymal stem cells. Stem Cells 2006; 24: 1613-1619.
37. Chino T, Tamai K, Yamazaki T, Otsuru S, Kikuchi Y, et al. Bone marrow cell transfer into fetal circulation can ameliorate genetic skin diseases by providing fibroblasts to the skin and inducing immune tolerance. Am J Pathol 2008; 173: 803-814.
38. Tamai K, Yamazaki T, Chino T, Ishii M, Otsuru S, et al. PDGFRalpha-positive cells in bone marrow are mobilized by high mobility group box 1 (HMGB1) to regenerate injured epithelia. Proc Natl Acad Sci USA 2011; 108: 6609-6614.
39. Aoi T, Yae K, Nakagawa M, Ichisaka T, Okita K, et al. Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science 2008; 321: 699-702.
40. Hanna J, Markoulaki S, Schorderet P, Carey BW, Beard C, et al. Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell 2008; 133: 250-264.
41. Makino S, Fukuda K, Miyoshi S, Konishi F, Kodama H, et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 1999; 103: 697-705.
42. Dezawa M, Ishikawa H, Itokazu Y, Yoshihara T, Hoshino M, et al. Bone marrow stromal cells generate muscle cells and repair muscle degeneration. Science 2005; 309: 314-317.
43. Oyagi S, Hirose M, Kojima M, Okuyama M, Kawase M, et al. Therapeutic effect of transplanting HGF-treated bone marrow mesenchymal cells into CCl4-injured rats. J Hepatol 2006; 44: 742-748.
44. Dezawa M, Kanno H, Hoshino M, Cho H, Matsumoto N, et al. Specific induction of neuronal cells from bone marrow stromal cells and application for autologous transplantation. J Clin Invest 2004; 113: 1701-1710.
45. Oswald J, Boxberger S, Jorgensen B, Feldmann S, Ehninger G, et al. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 2004; 22: 377-384.
46. Dezawa M, Takahashi I, Esaki M, Takano M, Sawada H. Sciatic nerve regeneration in rats induced by transplantation of in vitro differentiated bone-marrow stromal cells. Eur J Neurosci 2001; 14: 1771-1776.
47. Phinney DG, Prockop DJ. Concise review: Mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair-Current views. Stem Cells 2007; 25: 2896-2902.
48. Spees JL, Olson SD, Ylostalo J, Lynch PJ, Smith J, et al. Differentiation, cell fusion, and nuclear fusion during ex vivo repair of epithelium by human adult stem cells from bone marrow stroma. Proc Natl Acad Sci USA 2003; 100: 2397-2402.
49. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001; 410: 701-705.
50. Sakaida I, Terai S, Yamamoto N, Aoyama K, Ishikawa T, et al. Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice. Hepatology 2004; 40: 1304-1311.
51. Song L, Tuan RS. Transdifferentiation potential of human mesenchymal stem cells derived from bone marrow. Faseb J 2004; 18: 980-982.
52. Chen FG, Zhang WJ, Bi D, Liu W, Wei X, et al. Clonal analysis of nestin(-) vimentin(+) multipotent fibroblasts isolated from human dermis. J Cell Sci 2007; 120: 2875-2883.
53. Wesselschmidt RL. The teratoma assay: an in vivo assessment of pluripotency. Methods Mol Biol 2011; 767: 231-241.
54. Chou YF, Yabuuchi A. Murine embryonic stem cell derivation, in vitro pluripotency characterization, and in vivo teratoma formation. Curr Protoc Toxicol 2011; 2: 22.
55. Chou YF, Chen HH, Eijpe M, Yabuuchi A, Chenoweth JG, et al. The growth factor environment defines distinct pluripotent ground states in novel blastocyst-derived stem cells. Cell 2008; 135: 449-461.
56. Atari M, Caballé-Serrano J, Gil-Recio C, Giner-Delgado C, Martinez-Sarrá E, García-Fernández DA, Barajas M, Hernández-Alfaro F, Ferrés-Padró E, Giner-Tarrida L. The enhancement of osteogenesis through the use of dental pulp pluripotent stem cells in 3D. Bone 2012; 50:930-941.
57. Sakamoto S, Kojima F, Igarashi M, Sawa R, Umekita M, et al. Decalpenic acid, a novel small molecule from Penicillium verruculosum CR37010, induces early osteoblastic markers in pluripotent mesenchymal cells. J Antibiot (Tokyo) 2010; 63: 703-708.
58. Imazato S, Horikawa D, Takeda K, Kiba W, Izutani N, et al. Proliferation and differentiation potential of pluripotent mesenchymal precursor C2C12 cells on resin-based restorative materials. Dent Mater J 2010; 29: 341-346.
59. Tsagias N, Kouzi-Koliakos K, Koliakos I, Kostidou E, Karagiannis V, et al. Addition of adipose-derived stem cells in cord blood cultures stimulates their pluripotent differentiation. Transplant Proc 2009; 41: 4340-4344.
60. Lowry WE, Richter L, Yachechko R, Pyle AD, Tchieu J, et al. Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc Natl Acad Sci USA 2008; 105: 2883-2888.
61. Chan EM, Ratanasirintrawoot S, Park IH, Manos PD, Loh YH, et al. Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells. Nat Biotechnol 2009; 27: 1033-1037.
62. Lin Z, Perez P, Lei D, Xu J, Gao X, et al. Two-phase analysis of molecular pathways underlying induced pluripotent stem cell induction. Stem Cells 2011; 29: 1963-1974.
63. Ellenrieder V, Buck A, Gress TM. TGFbeta-regulated transcriptional mechanisms in cancer. Int J Gastrointest Cancer 2002; 31: 61-69.
64. Tang B, Yoo N, Vu M, Mamura M, Nam JS, et al. Transforming growth factor-beta can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model. Cancer Res 2007; 67: 8643-8652.
65. Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumor suppressor gene: Important milestones at the various steps of tumorigenesis. Genes Cancer 2011; 2: 466-474.
66. Haupt S, Haupt Y. Improving cancer therapy through p53 management. Cell Cycle 2004; 3: 912-916.
67. Lagarkova MA, Shutova MV, Bogomazova AN, Vassina EM, Glazov EA, et al. Induction of pluripotency in human endothelial cells resets epigenetic profile on genome scale. Cell Cycle 2010; 9: 937-946.
68. Ohm JE, Mali P, Van Neste L, Berman DM, Liang L, et al. Cancer-related epigenome changes associated with reprogramming to induced pluripotent stem cells. Cancer Res 2010; 70: 7662-7673.
69. Zhang X, Neganova I, Przyborski S, Yang C, Cooke M, et al. A role for NANOG in G1 to S transition in human embryonic stem cells through direct binding of CDK6 and CDC25A. J Cell Biol 2009; 184: 67-82.
70. Lee J, Go Y, Kang I, Han YM, Kim J. Oct-4 controls cell-cycle progression of embryonic stem cells. Biochem J 2010; 426: 171-181.
71. Huangfu D, Osafune K, Maehr R, Guo W, Eijkelenboom A, et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol 2008; 26: 1269-1275.
72. Li W, Wei W, Zhu S, Zhu J, Shi Y, et al. Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors. Cell Stem Cell 2009; 4: 16-19.
73. Lin T, Ambasudhan R, Yuan X, Li W, Hilcove S, et al. A chemical platform for improved induction of human iPSCs. Nat Methods 2009; 6: 805-808.
74. Chen J, Liu J, Han Q, Qin D, Xu J, et al. Towards an optimized culture medium for the generation of mouse induced pluripotent stem cells. J Biol Chem 2010; 285: 31066-31072.
75. Nishimura K, Sano M, Ohtaka M, Furuta B, Umemura Y, et al. Development of defective and persistent Sendai virus vector: A unique gene delivery/expression system ideal for cell reprogramming. J Biol Chem 2011; 286: 4760-4771.
76. Maekawa M, Yamaguchi K, Nakamura T, Shibukawa R, Kodanaka I, et al. Direct reprogramming of somatic cells is promoted by maternal transcription factor Glis1. Nature 2011; 474: 225-229.
77. Subramanyam D, Blelloch R. Watching reprogramming in real time. Nat Biotechnol 2009; 27: 997-998.
78. Masaki H, Ishikawa T, Takahashi S, Okumura M, Sakai N, et al. Heterogeneity of pluripotent marker gene expression in colonies generated in human iPS cell induction culture. Stem Cell Res 2007; 1: 105-115.
79. Trosko JE. Review paper: Cancer stem cells and cancer nonstem cells: From adult stem cells or from reprogramming of differentiated somatic cells. Vet Pathol 2009; 46: 176-193.
80. Trosko JE. From adult stem cells to cancer stem cells: Oct-4 Gene, cell-cell communication, and hormones during tumor promotion. Ann NY Acad Sci 2006; 1089: 36-58.